Study of Cisplatin/Vinorelbine +/- Cetuximab as First-line Treatment of Advanced Non Small Cell Lung Cancer (FLEX)

NCT00148798 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

1861

Enrollment

INDUSTRY

Sponsor class

Conditions

Non Small Cell Lung Cancer (NSCLC)

Interventions

DRUG: cetuximab + cisplatin + vinorelbine
DRUG: cisplatin + vinorelbine

Sponsor

Merck KGaA, Darmstadt, Germany